Preet Lal

Preet Lal

Auto-generated profile, based on publicly available information

Preet Lal

Washington University in St. Louis 2

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
YWYige Wu
Yige Wu
SCSiqi Chen
Siqi Chen
XYXiaolu Yang
Xiaolu Yang
KSKazuhito Sato
Kazuhito Sato
PLPreet Lal
Preet Lal
FCFeng Chen
Feng Chen
Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an avenue for enhancing treatment efficacy and addressing the limitations of current therapies. To identify effective strategies for treating RCC, we selected ten drugs guided by tumor biology to test in six RCC patient-derived xenograft (PDX) models. The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib and mTORC1/2 inhibitor sapanisertib emerged as the most effective drugs, particularly when combined. The combination demonstrated favorable tolerability and inhibited tumor growth or induced tumor regression in all models, including two from patients who experienced treatment failure with FDA-approved TKI and immunotherapy combinations. In cabozantinib-treated samples, imaging analysis revealed a significant reduction in vascular density, and single-nucleus RNA sequencing (snRNA-seq) analysis indicated a decreased proportion of endothelial cells in the tumors. SnRNA-seq data further identified a tumor subpopulation enriched with cell-cycle activity that exhibited heightened sensitivity to the cabozantinib and sapanisertib combination. Conversely, activation of the epithelial–mesenchymal transition pathway, detected at the protein level, was associated with drug resistance in residual tumors following combination treatment. The combination effectively restrained ERK phosphorylation and reduced expression of ERK downstream transcription factors and their target genes implicated in cell-cycle control and apoptosis. This study highlights the potential of the cabozantinib plus sapanisertib combination as a promising treatment approach for patients with RCC, particularly those whose tumors progressed on immune checkpoint inhibitors and other TKIs.Significance: The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.

17 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
Breast and prostate cancers are both hormone-driven adenocarcinomas that undergo analogous invasion programs. Using lightsheet microscopy on intact tumors, we identified transitional junctions between precancerous and invasive regions. We then developed a multimodal serial-section workflow integrating volumetric reconstruction with spatial transcriptomics. Analysis of 319 spatial assays from 51 cases revealed gene-expression features and novel structural insights defining the shift from precancer to invasive disease. In breast cancer, loss of MGP and PLAT was associated with invasive transition and promoted tumorigenesis in functional assays. In prostate cancer, GDF15, ALDH1A3, ANPEP, and FASN were upregulated along invasive progression, and their knockdown in PC-3 cells suppressed proliferation and migration. Enrichment of tumor-associated macrophages (SPP1⁺, MS4A6A⁺) along non-TNBC breast cancer transitions highlights immune involvement as a potential driver of invasiveness.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
SCSiqi Chen
Siqi Chen
ASAndrew Shinkle
Andrew Shinkle
YZYanyan Zhao
Yanyan Zhao
CMChia-Kuei Mo
Chia-Kuei Mo
AHAndrew Houston
Andrew Houston
LDLi Ding
Li Ding
Spatial transcriptomics (ST) and CO-Detection by indEXing (CODEX) are becoming the leading transformative approaches for studying spatially resolved tumor heterogeneity and immune complexity. To explore the application of these two cutting-edge technologies and to further investigate the complexities of tumor microenvironment, we applied 10x Visium Gene Expression platform and Akoya CODEX platform on surgical resections from pancreatic ductal adenocarcinoma (PDAC), breast cancer (BRCA), and clear cell renal carcinoma (ccRCC) patients. A total of 30+ protein markers were screened, verified, and conjugated as CODEX antibodies for the 3 types of cancers. Tumor microenvironment was vividly revealed by a set of cancer markers, immune markers, and stroma cells markers on a single ST slide and a single CODEX image. Notably, the distinct immune microenvironment was observed between tumor nests in the neighborhood in terms of cell types, number of cells, and cell distribution patterns. This work highlights the importance of direct visualization for tumor heterogeneity. It also provides a significant insight for understanding tumor complexity and a promising opportunity to benefit personalized medicine. Citation Format: Siqi Chen, Andrew Shinkle, Yanyan Zhao, Chia-Kuei Mo, Andrew Houston, Preet Lal, John M. Herndon, Ryan C. Fields, William Gillanders, Feng Chen, Li Ding. Spatial transcriptomics and multiplexed imaging to explore tumor heterogeneity and immune complexity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1710.

1 September 2026
Verified
Other
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
HT944B1_S2H3 DCIS_IDC ROI2 2Dscroll.

1 September 2026
Verified
Other
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
HT206B1 PanCKred MGPyellow SMAwhite.

1 September 2026
Verified
Other
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
Supplementary Mov. 16 from Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate